The fund, based in Herzliya, Israel, invests in biotechnology and clinical trial startups that are 2-3 years old. It typically invests in rounds with 5-6 participants and focuses on deals in the range of $10-50 million. While the fund has no specific preference for the number of founders, startups with 3 or 5+ founders have a lower chance of receiving investment. Some notable portfolio startups include BIOMx, Orasis Pharmaceuticals, and ChemomAb. The fund is involved in 2-6 deals per year and has had significant exits in 2018.